Cultures of hybridoma cells in bioreactors are commonly used to produce monoclonal antibodies. As an alternative to nonlinear model predictive control, which has recently been applied successfully to optimize the process productivity, a simpler control approach is developed in the present study. This strategy is based on a classical PI controller and software sensors for the reaction rates, which exploit the particular structure of the dynamic model. The dynamic behavior of the process can indeed be subdivided into four operating zones, depending on the overflow metabolism of the hybridoma cells. In addition, robustness toward model uncertainties and measurement noise is investigated.Fil: Gorrini, Federico Alberto. Consejo Nacional de Inves...
Mammalian cell cultures are valuable for synthesis of therapeutic proteins and antibodies. They are ...
Monoclonal antibodies (MAbs) have extensive biomedical application and are produced in mammalian cel...
In a decade when Industry 4.0 and quality by design are major technology drivers of biopharma, autom...
Fed-batch cultures of hybridoma cells are commonly used for the production of monoclonal antibodies ...
This paper describes the development of improved control strategies for the standard environmental c...
This paper describes the development of improved control strategies for the standard environmental c...
This paper describes the development of improved control strategies for the standard environmental c...
Hybridoma cells are commonly grown for the production of monoclonal antibodies (MAb). For monitoring...
Hybridoma cells are commonly grown for the production of monoclonal antibodies (MAb). For monitoring...
Finding optimal operating conditions fast with a scarce budget of experimental runs is a key problem...
The development of new biologics is becoming more challenging due to global competition and increase...
Monoclonal antibodies (MAbs) have an expanding market for use in diagnostic and therapeutic applicat...
This paper is dedicated to the experimental validation of a cascade control strategy for simultaneou...
The progressive acceleration of continuous bioprocessing method has become the focal point of advanc...
Leading pharmaceutical companies invest high percentage of their revenue in the improvement of exist...
Mammalian cell cultures are valuable for synthesis of therapeutic proteins and antibodies. They are ...
Monoclonal antibodies (MAbs) have extensive biomedical application and are produced in mammalian cel...
In a decade when Industry 4.0 and quality by design are major technology drivers of biopharma, autom...
Fed-batch cultures of hybridoma cells are commonly used for the production of monoclonal antibodies ...
This paper describes the development of improved control strategies for the standard environmental c...
This paper describes the development of improved control strategies for the standard environmental c...
This paper describes the development of improved control strategies for the standard environmental c...
Hybridoma cells are commonly grown for the production of monoclonal antibodies (MAb). For monitoring...
Hybridoma cells are commonly grown for the production of monoclonal antibodies (MAb). For monitoring...
Finding optimal operating conditions fast with a scarce budget of experimental runs is a key problem...
The development of new biologics is becoming more challenging due to global competition and increase...
Monoclonal antibodies (MAbs) have an expanding market for use in diagnostic and therapeutic applicat...
This paper is dedicated to the experimental validation of a cascade control strategy for simultaneou...
The progressive acceleration of continuous bioprocessing method has become the focal point of advanc...
Leading pharmaceutical companies invest high percentage of their revenue in the improvement of exist...
Mammalian cell cultures are valuable for synthesis of therapeutic proteins and antibodies. They are ...
Monoclonal antibodies (MAbs) have extensive biomedical application and are produced in mammalian cel...
In a decade when Industry 4.0 and quality by design are major technology drivers of biopharma, autom...